Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

IntroductionPatients with axial spondyloarthritis (axSpA) have a high disease burden mainly due to the rheumatic disease itself, and also exhibit accelerated atherosclerosis, that leads to a higher incidence of cardiovascular (CV) disease. Accordingly, the identification of biomarkers of CV risk and...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Sara Remuzgo-Martínez, Javier Rueda-Gotor, Verónica Pulito-Cueto, Raquel López-Mejías, Alfonso Corrales, Leticia Lera-Gómez, Raquel Pérez-Fernández, Virginia Portilla, Íñigo González-Mazón, Ricardo Blanco, Rosa Expósito, Cristina Mata, Javier Llorca, Vanesa Hernández-Hernández, Carlos Rodríguez-Lozano, Nuria Barbarroja, Rafaela Ortega-Castro, Esther Vicente, Cristina Fernández-Carballido, María Paz Martínez-Vidal, David Castro-Corredor, Joaquín Anino-Fernández, Diana Peiteado, Chamaida Plasencia-Rodríguez, Eva Galíndez-Agirregoikoa, María Luz García-Vivar, Nuria Vegas-Revenga, Irati Urionaguena, Oreste Gualillo, Juan Carlos Quevedo-Abeledo, Santos Castañeda, Iván Ferraz-Amaro, Miguel Á. González-Gay, Fernanda Genre
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Subjects:	irisin axial spondyloarthritis biomarker subclinical atherosclerosis cardiovascular risk disease severity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.894171/full